Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- April 1989
- Supplement
Novel Combination of Two Drugs (B)
Herzlinger, Regina E. "Novel Combination of Two Drugs (B)." Harvard Business School Supplement 189-169, April 1989.
- 2006
- Chapter
BioRisk: interleukin-2 from laboratory to market in the United States and Germany
By: Arthur A. Daemmrich
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (C)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (C)." Harvard Business School Case 603-045, June 2003. (Revised October 2004.)
- March 2002 (Revised May 2002)
- Case
Genzyme: Engineering the Market for Orphan Drugs
Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
- September 2001
- Supplement
Millennium Pharmaceuticals, Inc. (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case. View Details
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 602-063, September 2001.
- October 2000
- Teaching Note
Kendle International Inc. TN
By: Dwight B. Crane and Indra Reinbergs
Teaching Note for (9-200-033). View Details
- January 1999
- Background Note
Note on the Drugstore Industry
By: David E. Bell and Ann Leamon
In response to the twin pressures of cross-channel competition and the prevalence of third-party drug plans, drugstores have changed both how they go to market and what they offer once they get there. This note reviews the history of drugstores, presents the current... View Details
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 07 Jul 2016
- Blog Post
Can You Learn Finance through the Case Method?
Greetings from HBS! My name is Siri and I am a second-year student and a candidate for the joint MBA/MPP program between HBS and the Harvard Kennedy School of Government. Before graduate school, I worked for three years as a management consultant specializing in the... View Details
- 01 Sep 2006
- News
HBS Student Battles ALS
people every year, is not a high priority for either the public or pharmaceutical companies. To stimulate novel treatment ideas and to raise the venture funding needed to get those ideas to market, he launched two organizations. One is... View Details
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
- 26 Jun 2000
- Research & Ideas
What’s an Internet Business Model? Ask a Health Care Professional
out how to get into a clinical trial to try an experimental drug. For their part, physicians are often befuddled by difficult cases that don't respond to traditional therapies. And pharmaceutical companies, at the same time, are anxious... View Details
- 01 Oct 1998
- News
Playing to Win
in turning losing teams into winners, Louis-Dreyfus has an enviable record of reshaping underperforming companies into formidable competitors. A scion of one of France's most prominent business families, he rejuvenated IMS International, a struggling U.S. View Details
Keywords: Garry Emmons
- 15 Apr 2014
- News
Bertarelli Foundation Gift Names Deans' Health & Life Sciences Challenge Prize
entrepreneur who has had a successful career in business, finance, yachting, and philanthropy. He is the former CEO of Serono SA (formerly known Ares-Serono), a family-controlled global pharmaceuticals and biotechnology leader whose roots... View Details
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
problems that were posted? A: Innovations happen at the intersection of disciplines. People have talked about that a lot and I think we're providing some systematic evidence now with this study. Another example is that a pharmaceutical... View Details
Keywords: by Martha Lagace
- 22 Apr 2014
- First Look
First Look: April 22
constraints. Download working paper: https://www.hbs.edu/faculty/Pages/download.aspx?name=14-097.pdf The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories By:... View Details
Keywords: Sean Silverthorne
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
is Ciba Vision. Established in the early 1980s as a unit of the Swiss pharmaceutical giant Ciba-Geigy (now Novartis), the Atlanta-based Ciba Vision sells contact lenses and related eye-care products to optometrists and consumers. Although... View Details
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
prototype which we showcased at HBS and tested out in the NICU to observe its efficacy and nurse uptake. While we each embarked on different paths after the end of first year– from launching a new healthcare venture in Africa, to working at large View Details
- Fast Answer
Transforming Health Care Delivery
Books Books and journal titles on all aspects of the health care, life sciences and pharmaceutical sectors View Details